GSK PLC SEC Filings

GSK has reported a significant share buyback transaction on June 25, 2025. The company purchased 483,629 ordinary shares at prices ranging from 1,395.00p to 1,411.00p per share, with a volume-weighted average price of 1,400.74p.

Key transaction details:

• All trades were executed on the London Stock Exchange (XLON)
• Following this purchase, GSK holds 224,721,591 shares in treasury
• Total voting rights now stand at 4,090,623,881
• Treasury shares represent 5.49% of voting rights

This purchase is part of GSK's existing buyback program announced on June 4, 2025. Since the program's inception, the company has purchased 6,587,208 ordinary shares, demonstrating significant progress in their capital return strategy.

GSK plc reports a significant share buyback transaction on June 24, 2025. The company purchased 476,537 ordinary shares at prices ranging from 1,403.50p to 1,421.50p per share, with a volume-weighted average price of 1,411.62p.

Key transaction details:

• All trades executed on London Stock Exchange (XLON)
• Part of existing buyback program announced June 4, 2025
• Total shares purchased since program inception: 6,103,579
• Post-transaction treasury holdings: 224,237,962 shares
• Total voting rights: 4,091,107,510
• Treasury shares represent 5.48% of voting rights

The transaction demonstrates GSK's ongoing commitment to returning value to shareholders through its share repurchase program.

GSK has reported multiple share transactions by Sally Jackson, SVP of Global Communications & CEO Office, and her associated person Dylan Jackson on June 19, 2025. The transactions include:

• Sally Jackson gifted 1,400 ordinary shares to a family member at nil consideration
• Sally Jackson sold 1,395 shares at £14.3524 and purchased 1,387 shares at £14.3378 as part of an ISA transfer
• Dylan Jackson (PCA) sold 1,395 shares at £14.3524 and purchased 1,385 shares at £14.3537 as part of an ISA transfer

All transactions were conducted on the London Stock Exchange. These share movements represent portfolio restructuring into Individual Savings Accounts (ISAs) rather than significant changes in ownership positions. The transactions were reported in compliance with regulatory requirements for PDMRs (Persons Discharging Managerial Responsibilities) and their closely associated persons.

GSK announced a significant board-level change at one of its Non-Executive Directors' external commitments. Wendy Becker, who serves as GSK's Non-Executive Director and Chair of the Remuneration Committee, has been appointed as Chair of the Board of Sony Group Corporation, effective June 24, 2025. This represents a promotion from her previous position as Vice Chair of Sony's Board.

This disclosure, filed as a Form 6-K (foreign issuer report), reflects GSK's commitment to transparency regarding its directors' external appointments and potential commitments. The appointment was officially documented by Victoria Whyte, GSK's Company Secretary.

• Filing Date: June 28, 2025
• Effective Date of Appointment: June 24, 2025
• Key Personnel: Wendy Becker (Non-Executive Director)
• New Role: Chair of Sony Group Corporation Board
• Previous Role at Sony: Vice Chair of the Board

GSK has reported a significant share buyback transaction on June 23, 2025. The company purchased 483,823 ordinary shares through Merrill Lynch International at prices ranging from 1,398.00p to 1,414.50p per share, with a volume-weighted average price of 1,403.43p.

Key transaction details:

• All trades were executed on the London Stock Exchange (XLON)
• Following this purchase, GSK holds 223,761,425 shares in treasury
• Total voting rights now stand at 4,091,584,047
• Treasury shares represent 5.47% of voting rights

This purchase is part of GSK's existing buyback program announced on June 4, 2025. Since the program's inception, the company has purchased 5,627,042 ordinary shares, demonstrating significant progress in their capital return strategy.

GSK reported significant insider share purchases by multiple board members and executives on June 20, 2025. Key transactions include: Senior Independent Director Charles Bancroft purchased 2,021 ADSs at $37.8958 per share on NYSE, Lady Susan Symonds (PCA of Non-Executive Chair) acquired 1,350 ordinary shares at £14.3550 on LSE, and Independent Director Wendy Becker bought 545 ordinary shares at £14.3550. Multiple other directors including Dr Hal Barron, Dr Anne Beal, Dr Hal Dietz, Dr Jeannie Lee, and Dr Vishal Sikka also made purchases of ADSs ranging from 257 to 889 shares at $37.8958 each. These coordinated insider purchases by board members could signal confidence in GSK's future prospects. All transactions were executed across LSE and NYSE, demonstrating global board participation in share accumulation.

GSK announced that the European Medicines Agency (EMA) has accepted for review the marketing authorization application for linerixibat, a targeted inhibitor of the ileal bile acid transporter (IBAT), for treating cholestatic pruritus in patients with primary biliary cholangitis (PBC).

Key highlights:

• The application is based on positive results from the GLISTEN phase III trial, which met both primary and secondary endpoints
• Linerixibat demonstrated rapid, significant, and sustained improvement in cholestatic pruritus and itch-related sleep interference versus placebo
• The drug addresses an unmet medical need, as up to 90% of PBC patients experience pruritus, with current first-line treatments not reducing its severity
• The trial involved 238 PBC patients across 19 countries, marking it as the first truly global PBC study

This EMA acceptance follows FDA acceptance earlier in the month. Linerixibat has received orphan drug designation from both FDA and EMA, and is currently under review in the US and UK markets.

GSK announces a significant regulatory milestone as Japan's Ministry of Health, Labour and Welfare (MHLW) accepts their application to expand the use of Arexvy, their RSV vaccine, to adults aged 18-49 at increased risk of severe RSV disease.

Key developments:

• If approved, Arexvy would be the first RSV vaccine in Japan for this age group
• Application supported by positive Phase IIIb trial (NCT06389487) data showing non-inferior immune response in at-risk adults aged 18-49 compared to those 60+
• Currently approved in Japan for adults 60+ and at-risk adults 50+
• Trial involved 1,458 participants across 52 locations in 6 countries

RSV affects an estimated 64 million people globally annually and can lead to severe complications, particularly in at-risk populations. GSK is pursuing similar regulatory expansions in the US and Europe, positioning Arexvy as a leading preventive solution for RSV disease across multiple age groups.